Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Files An 8-K Results of Operations and Financial Condition

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March6, 2018, Biohaven Pharmaceutical Holding Company Ltd. (the “Registrant”) issued a press release announcing its financial results for the three months and full year ended December31, 2017. A copy of this press release is furnished herewith as Exhibit99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form8-K, the information in this Item 2.02, and Exhibit99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Biohaven Pharmaceutical Holding Co Ltd. Exhibit
EX-99.1 2 a18-7861_1ex99d1.htm EX-99.1 Exhibit 99.1   March 6,…
To view the full exhibit click here

About Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Recent Trading Information

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) closed its last trading session up +0.11 at 29.60 with shares trading hands.

An ad to help with our costs